NCT03924245 is a Phase 1 clinical trial of Entinostat in Fallopian Tube Cancer, sponsored by Vanderbilt-Ingram Cancer Center.

Who is sponsoring NCT03924245?

NCT03924245 is sponsored by Vanderbilt-Ingram Cancer Center.

What drugs are being tested in NCT03924245?

Interventions in NCT03924245: Entinostat, Olaparib.

What condition does NCT03924245 study?

NCT03924245 studies Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma.

Is NCT03924245 still recruiting?

NCT03924245 is currently terminated. Last updated 4 April 2022.

Last reviewed 2022-04-04 · How we verify

NCT03924245

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Terminated Phase 1 Last updated 4 April 2022

What this trial tests

Phase 1 trial testing Entinostat in Fallopian Tube Cancer in 3 participants. Terminated before completion.

Timeline

1 October 2020

Primary endpoint
4 February 2022

4 February 2022

Quick facts

Lead sponsor	Vanderbilt-Ingram Cancer Center
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	1 October 2020
Primary completion	4 February 2022
Estimated completion	4 February 2022
Sites	2 locations across United States

Drugs / interventions tested

Entinostat — full drug profile →
Olaparib (olaparib) — full drug profile →

Conditions studied

Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Fallopian Tube Carcinosarcoma — all drugs for Fallopian Tube Carcinosarcoma →
Fallopian Tube Clear Cell Adenocarcinoma — all drugs for Fallopian Tube Clear Cell Adenocarcinoma →
Fallopian Tube Endometrioid Adenocarcinoma — all drugs for Fallopian Tube Endometrioid Adenocarcinoma →

Sponsor

Vanderbilt-Ingram Cancer Center — full company profile →

Who can join

18 and older, female only, with Fallopian Tube Cancer or Fallopian Tube Carcinosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Olaparib and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.
McMullen M, Karakasis K, Madariaga A, Oza AM. · · 2020 · cited 127× · PMID 32560564 · DOI 10.3390/cancers12061607
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity.
Karagiannis D, Rampias T. · · 2021 · cited 58× · PMID 34298787 · DOI 10.3390/cancers13143575
Epigenetic drugs in cancer therapy.
Suraweera A, O'Byrne KJ, Richard DJ. · · 2025 · cited 50× · PMID 40011240 · DOI 10.1007/s10555-025-10253-7
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.
Jain A, Barge A, Parris CN. · · 2025 · cited 44× · PMID 39572842 · DOI 10.1038/s41388-024-03227-6
Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review.
Fernandez A, O'Leary C, O'Byrne KJ, Burgess J, et al · · 2021 · cited 32× · PMID 34307454 · DOI 10.3389/fmolb.2021.685440
Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Wilson AJ, Gupta VG, Liu Q, Yull F, et al · · 2022 · cited 26× · PMID 34933276 · DOI 10.1016/j.neo.2021.12.002

Verify or expand the search:

Other trials of Entinostat

Trials testing the same drug.

NCT07441486 — A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment · Phase 2 · not yet recruiting
NCT07261592 — Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer · Phase 1, PHASE2 · not yet recruiting
NCT05898828 — Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Th · Phase 1, PHASE2 · withdrawn
NCT05053971 — Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors · Phase 1, PHASE2 · recruiting
NCT04708470 — A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, · Phase 1, PHASE2 · active not recruiting

Other recruiting trials for Fallopian Tube Cancer

Currently open trials in the same condition.

NCT07402915 — Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian · Phase 1 · recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting
NCT06787612 — Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer · Phase 2 · recruiting
NCT07023484 — Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer · Phase 2 · recruiting
NCT07460180 — The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cy · Phase 1, PHASE2 · recruiting

Other Vanderbilt-Ingram Cancer Center trials

Trials by the same sponsor.

NCT06638398 — Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules · NA · active not recruiting
NCT06593106 — Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial · NA · recruiting
NCT06105801 — EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing · Phase 4 · recruiting
NCT06399640 — Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06016855 — Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03924245 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt-Ingram Cancer Center
Last refreshed: 4 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03924245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing